Compare Strategy Inc. (MSTR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Zoetis Inc — how do they compare? Strategy Inc. trades at $154.35 (market cap $60.40B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Strategy Inc. is far larger — about 2× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Zoetis Inc for 70 Days on average.
| MSTR | ZTS | |
|---|---|---|
Market Cap | $60.40B | $30.20B |
Volume | 23,421,830 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $320.29 | $147.53 |
52-Week Low | $82.31 | $69.09 |
Typical Hold Time | 112 Days | 70 Days |
Enterprise Value | $79.16B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $155.91, up 1.66% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $3.85 billion in 2025 on $477.23 million in revenue, with a negative net income margin of -806.35%. Recent news highlights Bitcoin's price surge and Citigroup raising its price target to $240, though the stock has shown volatility around Bitcoin price movements.
The outlook is polarized: analyst consensus is bullish with a $253.36 price target, but fundamental risks are high due to persistent losses, negative cash flow from operations, and heavy debt. Investment opportunity hinges on Bitcoin's performance, while risks include earnings misses and financial instability.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
